Novartis wants to claw back $209m in 'overpayments' to Genentech

Retrieved on: 2021-06-29 15:11:15

Tags for this article:

Click the tags to see associated articles and topics

Novartis wants to claw back $209m in 'overpayments' to Genentech. View article details on hiswai:

Excerpt

Roche subsidiary Genentech received $209.5 million in unnecessary payments from Novartis Pharma for a patent licensing deal and is now refusing ...

Article found on: www.lifesciencesipreview.com